These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
296 related articles for article (PubMed ID: 21795459)
21. Humoral response to the influenza A H1N1/09 monovalent AS03-adjuvanted vaccine in immunocompromised patients. Manuel O; Pascual M; Hoschler K; Giulieri S; Alves D; Ellefsen K; Bart PA; Venetz JP; Calandra T; Cavassini M Clin Infect Dis; 2011 Jan; 52(2):248-56. PubMed ID: 21288852 [TBL] [Abstract][Full Text] [Related]
22. Influenza viruses and cross-reactivity in healthy adults: humoral and cellular immunity induced by seasonal 2007/2008 influenza vaccination against vaccine antigens and 2009 A(H1N1) pandemic influenza virus. Iorio AM; Bistoni O; Galdiero M; Lepri E; Camilloni B; Russano AM; Neri M; Basileo M; Spinozzi F Vaccine; 2012 Feb; 30(9):1617-23. PubMed ID: 22245606 [TBL] [Abstract][Full Text] [Related]
23. Immunogenicity and safety of AS03-adjuvanted 2009 influenza A H1N1 vaccine in children 6-35 months. Carmona A; Omeñaca F; Tejedor JC; Merino JM; Vaman T; Dieussaert I; Gillard P; Arístegui J Vaccine; 2010 Aug; 28(36):5837-44. PubMed ID: 20600478 [TBL] [Abstract][Full Text] [Related]
24. Assessment of the immunogenicity and safety of varying doses of an MF59®-adjuvanted cell culture-derived A/H1N1 pandemic influenza vaccine in Japanese paediatric, adult and elderly subjects. Fukase H; Furuie H; Yasuda Y; Komatsu R; Matsushita K; Minami T; Suehiro Y; Yotsuyanagi H; Kusadokoro H; Sawata H; Nakura N; Lattanzi M Vaccine; 2012 Jul; 30(33):5030-7. PubMed ID: 22472791 [TBL] [Abstract][Full Text] [Related]
25. Immunogenicity and safety of the influenza A/H1N1 2009 inactivated split-virus vaccine in young and older adults: MF59-adjuvanted vaccine versus nonadjuvanted vaccine. Cheong HJ; Song JY; Heo JY; Noh JY; Choi WS; Park DW; Wie SH; Kim WJ Clin Vaccine Immunol; 2011 Aug; 18(8):1358-64. PubMed ID: 21715575 [TBL] [Abstract][Full Text] [Related]
26. Dose-range study of MF59-adjuvanted versus nonadjuvanted monovalent A/H1N1 pandemic influenza vaccine in six- to less than thirty-six-month-old children. Block SL; Ruiz-Palacios GM; Guerrero ML; Beygo J; Sales V; Holmes SJ Pediatr Infect Dis J; 2012 Jul; 31(7):e92-8. PubMed ID: 22481427 [TBL] [Abstract][Full Text] [Related]
27. Efficacy, immunogenicity, and safety evaluation of an MF59-adjuvanted quadrivalent influenza virus vaccine compared with non-adjuvanted influenza vaccine in children: a multicentre, randomised controlled, observer-blinded, phase 3 trial. Vesikari T; Kirstein J; Devota Go G; Leav B; Ruzycky ME; Isakov L; de Bruijn M; Oberye J; Heijnen E Lancet Respir Med; 2018 May; 6(5):345-356. PubMed ID: 29631857 [TBL] [Abstract][Full Text] [Related]
28. Pre-vaccination immunity and immune responses to a cell culture-derived whole-virus H1N1 vaccine are similar to a seasonal influenza vaccine. Ehrlich HJ; Müller M; Kollaritsch H; Pinl F; Schmitt B; Zeitlinger M; Loew-Baselli A; Kreil TR; Kistner O; Portsmouth D; Fritsch S; Maritsch F; Aichinger G; Pavlova BG; Barrett PN Vaccine; 2012 Jun; 30(30):4543-51. PubMed ID: 22475864 [TBL] [Abstract][Full Text] [Related]
29. Randomized, multicenter trial of a single dose of AS03-adjuvanted or unadjuvanted H1N1 2009 pandemic influenza vaccine in children 6 months to <9 years of age: safety and immunogenicity. Langley JM; Reich D; Aggarwal N; Connor D; Lebel MH; Gupta A; Garfield H; Li P; Madan A; Vaughn DW Pediatr Infect Dis J; 2012 Aug; 31(8):848-58. PubMed ID: 22801094 [TBL] [Abstract][Full Text] [Related]
30. Enhanced immunogenicity of seasonal influenza vaccines in young children using MF59 adjuvant. Vesikari T; Pellegrini M; Karvonen A; Groth N; Borkowski A; O'Hagan DT; Podda A Pediatr Infect Dis J; 2009 Jul; 28(7):563-71. PubMed ID: 19561422 [TBL] [Abstract][Full Text] [Related]
31. Response to 2009 pandemic and seasonal influenza vaccines co-administered to HIV-infected and HIV-uninfected former drug users living in a rehabilitation community in Italy. Pariani E; Boschini A; Amendola A; Poletti R; Anselmi G; Begnini M; Ranghiero A; Cecconi G; Zanetti AR Vaccine; 2011 Nov; 29(49):9209-13. PubMed ID: 21974995 [TBL] [Abstract][Full Text] [Related]
32. Immunogenicity of avian influenza A/Anhui/01/2005(H5N1) vaccine with MF59 adjuvant: a randomized clinical trial. Belshe RB; Frey SE; Graham IL; Anderson EL; Jackson LA; Spearman P; Edupuganti S; Mulligan MJ; Rouphael N; Winokur P; Dolor RJ; Woods CW; Walter EB; Chen WH; Turley C; Edwards KM; Creech CB; Hill H; Bellamy AR; JAMA; 2014 Oct; 312(14):1420-8. PubMed ID: 25291578 [TBL] [Abstract][Full Text] [Related]
33. Effect of Varying Doses of a Monovalent H7N9 Influenza Vaccine With and Without AS03 and MF59 Adjuvants on Immune Response: A Randomized Clinical Trial. Jackson LA; Campbell JD; Frey SE; Edwards KM; Keitel WA; Kotloff KL; Berry AA; Graham I; Atmar RL; Creech CB; Thomsen IP; Patel SM; Gutierrez AF; Anderson EL; El Sahly HM; Hill H; Noah DL; Bellamy AR JAMA; 2015 Jul; 314(3):237-46. PubMed ID: 26197184 [TBL] [Abstract][Full Text] [Related]
34. Safety and immunogenicity of a monovalent MF59®-adjuvanted A/H1N1 vaccine in HIV-infected children and young adults. Palma P; Romiti ML; Bernardi S; Pontrelli G; Mora N; Santilli V; Tchidjou HK; Aquilani A; Cotugno N; Alghisi F; Lucidi V; Rossi P; Douagi I Biologicals; 2012 Mar; 40(2):134-9. PubMed ID: 22261282 [TBL] [Abstract][Full Text] [Related]
35. Homologous and heterologous antibody responses to a one-year booster dose of an MF59(®) adjuvanted A/H5N1 pre-pandemic influenza vaccine in pediatric subjects. Vesikari T; Forstén A; Borkowski A; Gaitatzis N; Banzhoff A; Clemens R Hum Vaccin Immunother; 2012 Jul; 8(7):921-8. PubMed ID: 22777094 [TBL] [Abstract][Full Text] [Related]
36. Evaluation of non-inferiority of intradermal versus adjuvanted seasonal influenza vaccine using two serological techniques: a randomised comparative study. Van Damme P; Arnou R; Kafeja F; Fiquet A; Richard P; Thomas S; Meghlaoui G; Samson SI; Ledesma E BMC Infect Dis; 2010 May; 10():134. PubMed ID: 20504306 [TBL] [Abstract][Full Text] [Related]
37. A phase II, randomised clinical trial to demonstrate the non-inferiority of low-dose MF59-adjuvanted pre-pandemic A/H5N1 influenza vaccine in adult and elderly subjects. Czajka H; Unal S; Ulusoy S; Usluer G; Strus A; Sennaroglu E; Guzik J; Topeli Iskit A; Dargiewicz A; Musial D; Caylan R; Dziduch J; Eskioglu E; Hasiec B; Cwinarowiczliwa E; Belli R; Abdel-Messih IA; Beygo J; Fragapane E J Prev Med Hyg; 2012 Sep; 53(3):136-42. PubMed ID: 23362618 [TBL] [Abstract][Full Text] [Related]
38. Long-term and cross-reactive immunogenicity of inactivated trivalent influenza vaccine in the elderly: MF59-adjuvanted vaccine versus unadjuvanted vaccine. Song JY; Cheong HJ; Noh JY; Seo YB; Choi WS; Cho GJ; Hwang TG; Kim WJ J Med Virol; 2013 Sep; 85(9):1591-7. PubMed ID: 23852684 [TBL] [Abstract][Full Text] [Related]
39. Immunogenicity and Safety of an MF59-adjuvanted Quadrivalent Seasonal Influenza Vaccine in Young Children at High Risk of Influenza-associated Complications: A Phase III, Randomized, Observer-blind, Multicenter Clinical Trial. Esposito S; Fling J; Chokephaibulkit K; de Bruijn M; Oberye J; Zhang B; Vossen J; Heijnen E; Smolenov I Pediatr Infect Dis J; 2020 Aug; 39(8):e185-e191. PubMed ID: 32404782 [TBL] [Abstract][Full Text] [Related]
40. Characterization and long-term persistence of immune response following two doses of an AS03A-adjuvanted H1N1 influenza vaccine in healthy Japanese adults. Ikematsu H; Nagai H; Kawashima M; Kawakami Y; Tenjinbaru K; Li P; Walravens K; Gillard P; Roman F Hum Vaccin Immunother; 2012 Feb; 8(2):260-6. PubMed ID: 22426369 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]